Treatment
Tofacitinib clinical trials
We’re tracking 38 recruiting studies that include Tofacitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06095128RecruitingPhase 4
Vedolizumab and tofacitinib study for ulcerative colitis
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
Dothan, AlabamaAges 18–65 - NCT03681275RecruitingPhase 2
Prevent diaphragm weakness after esophagus surgery
This trial studies a medicine that blocks Janus kinase (JAK) signals, to help prevent breathing muscle weakness in the diaphragm after esophagus removal surgery. It may help patients who need a ventilator during recovery avoid “ventilator-induced” diaphragm dysfunction.
Stanford, CaliforniaAges 18 years+ - NCT06698822RecruitingPhase 2
Tofacitinib cream for early-stage cutaneous T-cell lymphoma
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
Houston, TexasAges 18 years+ - NCT05102448RecruitingPhase 4
Tofacitinib vs methotrexate for active Takayasu’s arteritis
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT05313620RecruitingPhase 4
Tofacitinib effect on clotting tests in ulcerative colitis
This study looks at how tofacitinib (and related medicines) may affect clotting and blood-platelet function, and whether this could relate to blood clot risk. It includes detailed blood and stool/colonoscopy-related testing in adults with ulcerative colitis and in some people without it.
Madrid, MadridAges 18 years+ - NCT05845723RecruitingPhase 2
Study drugs for blood-vessel Behçet’s to reduce inflammation
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
Beijing, Beijing MunicipalityAges 18–65 - NCT06112665RecruitingPhase 4
Tofacitinib for early active axial spondyloarthritis
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
BerlinAges 18–45 - NCT06172361RecruitingPhase 3
Tofacitinib and steroid taper for PMR
This study tests whether a daily pill (tofacitinib) combined with a short course of steroids can help people with active PMR use less steroids over time. You must have high disease activity and not have taken steroids or biologics in the past two weeks.
Hangzhou, ZhejiangAges 50–88 - NCT06301373Recruiting
Combining methotrexate and tofacitinib for rheumatoid arthritis
This study tests whether combining two medicines—methotrexate and tofacitinib—works better for people with a specific type of rheumatoid arthritis. It may be a good fit if you have moderate to severe arthritis, have had a joint biopsy that shows a certain cell pattern, and haven't used similar treatments before.
Foshan, GuangdongAges 18–65 - NCT06707246Recruiting
Comparing secukinumab and tofacitinib for hidradenitis suppurativa
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
Hangzhou, ZhejiangAges 18–75 - NCT06979271Recruiting
Testing a new drug combo for tough rheumatoid arthritis
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
Hangzhou, ZhejiangAges 18–85 - NCT07131813RecruitingPhase 4
Tofacitinib for oral lichen planus
This trial tests whether adding the drug tofacitinib to standard treatment helps reduce symptoms of oral lichen planus, a chronic inflammatory mouth condition. It is for people with moderate to severe disease who have not taken certain immune-suppressing medicines recently.
Bhubaneswar, OdishaAges 18 years+ - NCT07261306RecruitingEarly Phase 1
Methotrexate vs tofacitinib pills for plaque psoriasis
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
Lahore, Punjab ProvinceAges 18–70 - NCT07281456RecruitingPhase 2
Testing a new oral drug for Sjögren's disease safety
This study tests the safety of a daily pill called Tofacitinib for adults with mild-to-moderate Sjögren's disease. It aims to see if this drug helps manage symptoms when other treatments haven't worked well.
Bethesda, MarylandAges 18–75 - NCT07343635Recruiting
Anti-inflammatory therapy with yellow light for rosacea
This trial tests a combination of an anti-inflammatory gel (Hirudoid), yellow light therapy, and two oral medications (tofacitinib and doxycycline) for Chinese adults with mild to moderate rosacea that causes redness and visible blood vessels. The goal is to see if this approach reduces symptoms safely.
Yiwu, ZhejiangAges 18–70 - NCT07547930RecruitingPhase 2
Tofacitinib for Steroid-Resistant Thyroid Eye Disease
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
Xiamen, FujianAges 18–75 - NCT07554820RecruitingPhase 4
Heart Protection in Rheumatoid Arthritis With New Medications
This study compares two treatment approaches for people with active rheumatoid arthritis who also have heart disease risk factors. It tests whether a newer drug called tofacitinib, combined with cholesterol medication, can better protect the heart than traditional TNF-inhibitor treatments.
Lahore, Punjab ProvinceAges 50–85 - NCT06687551RecruitingPhase 4
Testing lower doses of JAK inhibitors for rheumatoid arthritis
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Toulouse, OccitanieAges 18–65 - NCT06660329Enrolling by invitationPhase 4
Tofacitinib for hard-to-treat Blau syndrome
This study tests if the drug tofacitinib (a JAK inhibitor) can help people with Blau syndrome whose symptoms did not improve with other treatments. Blau syndrome is a rare genetic condition that causes inflammation in the skin, joints, eyes, and other organs.
BeijingAges birth–18 years - NCT06998875RecruitingPhase 4
Study of avastin and tofacitinib for skin amyloidosis
This trial looks at people with primary cutaneous amyloidosis who have been treated with Avastin Capsules or Tofacitinib Citrate. It aims to track how well these medications work and if they are safe over time.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06688838Enrolling by invitation
JAK inhibitor for Blau syndrome
This trial tests a new oral drug that blocks inflammation in people with Blau syndrome, a rare genetic condition causing joint, eye, and skin problems. The goal is to see if the drug can reduce symptoms and improve quality of life.
Wuhan, HubeiAges Any age - NCT04876781Recruiting
Track safety of Xeljanz XR in Korea
This study collects real-world safety information about Xeljanz XR after it has been approved. It includes people with certain immune-related joint diseases and checks for side effects in everyday use.
SeoulAges 18 years+ - NCT06654882RecruitingPhase 3
Switching medications after first treatment fails in juvenile arthritis
This study tests different medication sequences for children and teens with polyarticular juvenile idiopathic arthritis (JIA) who still have moderate or high disease activity after at least 3 months on their first tumor necrosis factor inhibitor (TNFi) therapy. The goal is to find the best next step to control symptoms and improve quality of life.
San Francisco, CaliforniaAges 2–17 - NCT07406035RecruitingPhase 2
Testing TQH3906 for active psoriatic arthritis
This trial tests a new capsule, TQH3906, for people with active psoriatic arthritis who haven't had success with other treatments. It aims to see if the drug is safe and works well for joint and skin symptoms.
Bozhou, AnhuiAges 18–70
What Tofacitinib is being studied for
Conditions with recruiting Tofacitinib studies.
Common questions
- Are there clinical trials studying Tofacitinib?
- Yes. Clin2 currently lists 38 recruiting studies that include Tofacitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tofacitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tofacitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tofacitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.